Prime Medicine (PRME) Return on Capital Employed (2022 - 2025)
Historic Return on Capital Employed for Prime Medicine (PRME) over the last 4 years, with Q3 2025 value amounting to 0.69%.
- Prime Medicine's Return on Capital Employed rose 1900.0% to 0.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.69%, marking a year-over-year increase of 1900.0%. This contributed to the annual value of 0.97% for FY2024, which is 500.0% down from last year.
- As of Q3 2025, Prime Medicine's Return on Capital Employed stood at 0.69%, which was up 1900.0% from 0.76% recorded in Q2 2025.
- Over the past 5 years, Prime Medicine's Return on Capital Employed peaked at 0.43% during Q1 2023, and registered a low of 1.28% during Q4 2023.
- In the last 4 years, Prime Medicine's Return on Capital Employed had a median value of 0.75% in 2025 and averaged 0.76%.
- Per our database at Business Quant, Prime Medicine's Return on Capital Employed tumbled by -8300bps in 2023 and then surged by 5500bps in 2024.
- Quarter analysis of 4 years shows Prime Medicine's Return on Capital Employed stood at 0.45% in 2022, then plummeted by -187bps to 1.28% in 2023, then soared by 43bps to 0.73% in 2024, then grew by 6bps to 0.69% in 2025.
- Its last three reported values are 0.69% in Q3 2025, 0.76% for Q2 2025, and 0.74% during Q1 2025.